Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Mayo Clinic Partners in Study of Drug That May Bolster Immune System

By Drug Discovery Trends Editor | December 30, 2008

A new drug that could help cancer patients by stimulating their immune system is being tested by Mayo Clinic in conjunction with the Translational Genomic Research Institute (TGen) and Scottsdale Healthcare.

Clinical trials are being conducted at Mayo and Scottsdale Healthcare to study the drug, VTX-2337, which is a new, novel, small molecule aimed at activating immune cells in the blood and lymph nodes surrounding a tumor.

The Phase 1 trial, a year-long test in humans, will focus on the drug’s safety. If successful, Phase 2 will test the drug’s effectiveness in treating tumors.

Cancer — and its treatment — can weaken the body’s immune system by affecting the blood cells that protect humans against disease and germs, according to the American Cancer Society. The body then has a difficult time fighting infection. The hope is that the new drug will prompt a cancer patient’s immune system to slow down the growth of tumors — or even shrink them.

It is believed that the drug will work by tricking the body’s immune system into attacking the cancer, which is what the immune system typically does when attacking a bacterial infection.

According to Peter Cohen, M.D., Mayo Clinic researcher in Hematology/Oncology, the drug mimics a bacterial signal that basically alerts the body about a potentially life-threatening event, such as infection. Immunotherapy, notes Dr. Cohen, has long been studied as a strategy to fight cancer.

Researchers are hopeful that this new molecule may play an important role in humans and have broad application in the treatment of cancer.

Release Date: December 24, 2008
Source: Mayo Clinic


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE